Abstracts tagged "rheumatoid arthritis"

Abstract Number: 817 • 2019 ACR/ARP Annual Meeting
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Shunsei Hirohata¹, Tatsuo Nagai ², Tetsuya Tomita ³ and Hideki Yoshikawa ³, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Tatsuno, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Osaka University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia, consisting of type A macrophage-like synoviocytes and type B fibroblast-like synoviocytes (FLS).…
Abstract Number: 1000 • 2019 ACR/ARP Annual Meeting
RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Sang-Il Lee¹, Hae Sook Noh ² and Yun-Hong Cheon ¹, ¹Divison of Rheumatology, Gyeongsang National University Hospital, Jin-Ju, Republic of Korea, ²Gyeongsang University Hospital, Jinju, Republic of Korea
Background/Purpose: Nuclear factor-kappaB (NF-kappaB) and extracellular-signal-regulated kinase (ERK) have been implicated as a therapeutic target for the treatment of rheumatoid arthritis (RA). Raf kinase inhibitory…
Abstract Number: 1438 • 2019 ACR/ARP Annual Meeting
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Toshihisa Kojima¹, Shuji Asai ¹, Masahiro Hanabayashi ², Masatoshi Hayashi ³, Nobunori Takahashi ¹, Yachiyo Kuwatsuka ⁴, Masahiko Ando ⁴ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Ichinomiya Municipal Hospital, Ichinomiya, Japan, ³Hayashi Orthopedic Clinic, Nagano, Japan, ⁴Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Biological DMARD (bDMARD) concomitant with methotrexate (MTX) has made great progress in the treatment of rheumatoid arthritis (RA) in these decades. There are various…
Abstract Number: 2247 • 2019 ACR/ARP Annual Meeting
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Raj Vachhani¹, Lang Chen ¹, Ronan O'Beirne ², Joshua Melnick ³, Eric Ruderman ⁴, Jeffrey Curtis ¹ and Maria Danila ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴Northwestern University Feinberg School of Medicine, Division of Rheumatology, Evanston, IL
Background/Purpose: Evidence-based guidelines recommend escalation of therapy in patients with rheumatoid arthritis (RA) with inadequately controlled disease. However, some patients are hesitant to change therapies…
Abstract Number: 2768 • 2019 ACR/ARP Annual Meeting
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo¹, Israel Nieto-Gañán ², Cristina Sobrino ³, Victoria Navarro-Compán ⁴, Ana Martínez-Feito ⁵, Carlota García-Hoz ⁶, Paloma Lapuente-Suanzes ², javier Bachiller ³, Gema Bonilla ⁷, Cristina Pijoán-Moratalla ³, Garbiñe Roy ², Mónica Vázquez Díaz ³, Alejandro Balsa ⁷, Luisa María Villar ², Dora Pascual-Salcedo ¹, Eulalia Rodríguez-Martín ² and Chamaida Plasencia ⁷, ¹Immuno-Rheumatology Research Group, IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ³Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁴University Hospital La Paz, IdiPaz, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, IdiPAZ & Immunology Department. La Paz University Hospital, MADRID, Spain, ⁶Immunology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, ⁷Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain
Background/Purpose: According to the EULAR recommendations, the therapeutic objective in patients with rheumatoid arthritis (RA) should be remission. Biological therapies, as TNF inhibitors (TNFi), have…
Abstract Number: 35 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis
Yuko Okamoto¹, Elena W.Y. Hsieh ², Ronald P. Schuyler ³, Jennifer Seifert ⁴, Marie Feser ⁵, Jill Norris ⁶, M. Kristen Demoruelle ⁷, Kevin Deane ⁵ and V. Michael Holers ⁴, ¹University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA and Tokyo Women’s Medical University School of Medicine, Department of Rheumatology, Tokyo, Japan, Denver, ²University of Colorado School of Medicine, Department of Immunology and Microbiology, Aurora, CO, USA and University of Colorado School of Medicine, Children’s Hospital Colorado, Department of Pediatrics, Section of Allergy & Immunology, Aurora, CO, USA, Denver, ³University of Colorado School of Medicine, Department of Immunology and Microbiology Aurora, CO, USA, Denver, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁶Colorado School of Public Health, Department of Epidemiology, Aurora, CO, USA, Denver, ⁷University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Our group previously demonstrated that sputum neutrophils from subjects At-Risk for future rheumatoid arthritis (RA) spontaneously form neutrophil extracellular traps with elevated histone H3…
Abstract Number: 515 • 2019 ACR/ARP Annual Meeting
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
Michael Weinblatt¹, Glen Thomson ², Kun Chen ³, Sebastian Meerwein ⁴, Casey Schlacher ⁵ and John Cush ⁶, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²CIADS Research, Winnipeg, Canada, ³AbbVie Inc., North Chicago, ⁴AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶5Baylor University Medical Center, Dallas
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, demonstrated efficacy in the SELECT-BEYOND study in patients (pts) with moderate to severe rheumatoid arthritis (RA) on a stable…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Colin Edgerton¹, Janna Radtchenko ² and V. Michael Holers ³, ¹Articularis Healthcare, Charleston, ²Trio Health, La Jolla, CA, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver
Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Chrong-Reen Wang¹, Shih-Yao Chen ¹, Yu-Chi Chou ², Chao-Liang Wu ³, Yu-Ting Lo ¹ and Ai-Li Shiau ⁴, ¹National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ²Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), ³National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), ⁴National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
Abstract Number: 2249 • 2019 ACR/ARP Annual Meeting
Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment
Aniket Kawatkar¹, ¹Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid arthritis (RA) exerts multifaceted burden through medical expenditures, productivity losses, disability, and intangible costs of pain, fatigue, and loss of functional capacity. Patient…
Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate
Amee Sonigra ¹, Hendrik Nel ², Nishta Ramnoruth ², Meghna Talekar ², Joanne Tesiram ³, Frederik Stuurman ⁴, Lavinia Proctor ⁵, Helen Roberts ⁶, Robin Thurmond ⁷, Phillip Vecchio ³, Ian Gourley ⁸, Mark Rigby ⁹, Nathan Felix ¹⁰, Stephane Becart ¹¹, Kim Campbell ¹² and Ranjeny Thomas², ¹Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, ²University of Queensland, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Centre for Human Drug Research, Leiden, Netherlands, ⁵Dendright, Woolloongabba, Australia, ⁶Dendright, Woolloongabba, Queensland, Australia, ⁷Janssen Research & Development, La Jolla, CA, ⁸Janssen Research & Development, Springhouse, ⁹Janssen Research & Development, La Jolla, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen R&D, La Jolla, CA, ¹²Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…
Abstract Number: 38 • 2019 ACR/ARP Annual Meeting
Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis
Wen Shi Lee¹, Masaru Kato ¹, Eri Sugawara ¹, Michihiro Kono ¹, Yuki Kudo ², Michihito Kono ³, Yuichiro Fujieda ¹, Toshiyuki Bohgaki ¹, Olga Amengual ¹, Kenji Oku ¹, Shinsuke Yasuda ¹ and Tatsuya Atsumi ⁴, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Hokkaido University, Sapporo, Japan
Background/Purpose: Joint destructions progress throughout the course of rheumatoid arthritis (RA) without complete remission. Optineurin (OPTN) is an autophagy receptor with multiple functions related to…
Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Mark Genovese¹, Kurt de Vlam ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Iyabode Tiamiyu ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, David Walker ⁶, Tsutomu Takeuchi ⁷ and Kenneth Kalunian ⁸, ¹Stanford University, Stanford, CA, ²Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Northumbria Healthcare, Northumbria, United Kingdom, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
Abstract Number: 928 • 2019 ACR/ARP Annual Meeting
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi ², Aileen Pangan ³, Alan Friedman ³, Su Chen ³, Maureen Rischmueller ⁴, Ricardo Blanco ⁵, Ricardo Machado Xavier ⁶ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie Inc., North Chicago, ⁴Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, was efficacious as monotherapy upto 24 weeks (wks) in MTX-naive patients (pts) with active RA.1 To assess safety and efficacy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].